1. Home
  2. SSTK vs DRUG Comparison

SSTK vs DRUG Comparison

Compare SSTK & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shutterstock Inc.

SSTK

Shutterstock Inc.

HOLD

Current Price

$16.75

Market Cap

596.1M

Sector

Technology

ML Signal

HOLD

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$74.28

Market Cap

707.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSTK
DRUG
Founded
2003
2019
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Pharmaceuticals and Biotechnology
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
596.1M
707.1M
IPO Year
2012
2020

Fundamental Metrics

Financial Performance
Metric
SSTK
DRUG
Price
$16.75
$74.28
Analyst Decision
Buy
Strong Buy
Analyst Count
2
6
Target Price
$25.00
$129.25
AVG Volume (30 Days)
241.6K
174.6K
Earning Date
04-28-2026
05-15-2026
Dividend Yield
8.61%
N/A
EPS Growth
23.76
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$4.35
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.36
$23.18
52 Week High
$29.50
$123.75

Technical Indicators

Market Signals
Indicator
SSTK
DRUG
Relative Strength Index (RSI) 48.64 34.43
Support Level $15.88 $69.83
Resistance Level $17.67 $77.01
Average True Range (ATR) 0.61 4.88
MACD -0.03 -1.82
Stochastic Oscillator 56.54 11.47

Price Performance

Historical Comparison
SSTK
DRUG

About SSTK Shutterstock Inc.

Shutterstock Inc is a U.S.-based company that is engaged in the provision of digital content. The content segment, whose offerings include licenses for Images, Footage, Music, 3 Dimensional, and Generative AI content. Data, Distribution, and Service offerings address customer demand for products and services that are beyond its Content licenses. The company generates the majority of its revenue from Content offerings. Geographically the company generates the majority of its revenue from the Domestic market, but also has its presence in Europe and Rest of the Countries.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: